How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

156 results for

HIV related Myelopathy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Leptomeningeal gadolinium enhancement across the spectrum of chronic neuroinflammatory diseases. (PubMed)

conditions (18/51 cases, 35%) than in noninflammatory neurologic conditions (3/38, 8%) and healthy volunteers (5/66, 8%). The highest prevalence of LME was detected in HTLV infection (17/38 cases, 45%), particularly in the setting of HTLV-associated myelopathy (14/25 cases, 56%). LME also frequently occurred in HIV infection (13/61 cases, 21%). Unlike in MS, LME is not associated with lower brain and cortical volumes in non-MS inflammatory neurologic conditions, including HTLV and HIV infection.Despite (...) its relevance to MS pathogenesis and cortical pathology, LME is not specific to MS, occurring frequently in non-MS inflammatory neurologic conditions and especially in those patients with HTLV-associated myelopathy. Overall, this strengthens the notion that LME localizes inflammation-related focal disruption of the blood-meninges barrier and associated scarring.© 2017 American Academy of Neurology.

Full Text available with Trip Pro

2017 Neurology

42. MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study

Inflammatory Demyelinating Polyneuropathy Dermatomyositis HTLV associated myelopathy-tropical spastic paraparesis (HAM-TSP) Meningitis Mild Cognitive Impairment Multiple Sclerosis (MS) Polymyositis Spastic Paraparesis Sciatica Exclusion Criteria: HTLV Infected: specimens with a known infection or history of HIV, HCV or HBV specimens not meeting specimen labeling collection / handling criteria Neurological Disorders specimens not meeting specimen labeling collection / handling criteria Contacts (...) Biomedicals, LLC Study Details Study Description Go to Brief Summary: This post-market study is intended to assess the performance of the HTLV Blot 2.4 in repository serum/plasma specimens with neurological disorders (n=100) or an HTLV known positive infection (n=50). Condition or disease Intervention/treatment Phase HTLV-I Infections HTLV-II Infections Human T-lymphotropic Virus 1 Human T-lymphotropic Virus 2 HTLV I Associated T Cell Leukemia Lymphoma HTLV I Associated Myelopathies Diagnostic Test: MP

2017 Clinical Trials

43. Gene Therapy of Beta Thalassemia Using a Self-inactivating Lentiviral Vector

(other than Bowen disease or cervical cancer); or has family history of cancer. Myelopathy, tumor-related cytogenetic changes or other more severe blood diseases. Has alcoholism experience within 6 months prior to enrollment. History of epilepsy. History of bone marrow transplantation. Existence of an available HLA-identical related donor. Pregnant or lactating females. Subject infected with HCV (HCV antibody positive), HBV (HBsAg positive), HIV (HIV antibody positive), HTLV (HTLV antibody positive (...) or disease Intervention/treatment Phase Beta-Thalassemia Genetic: Gene-modified autologous stem cells Not Applicable Detailed Description: Thalassemia is considered the most common genetic disorder worldwide. Beta-thalassemia is caused by mutations in the beta-globin gene which encodes the beta-globin protein, leading to the ineffective erythropoiesis, hemolysis and anemia. Currently, the only cure for thalassemia is bone marrow transplantation from a related, compatible donor, which has, however

2017 Clinical Trials

44. Central Pain Study for ABX-1431

: Randomized Intervention Model: Crossover Assignment Masking: Triple (Participant, Investigator, Outcomes Assessor) Primary Purpose: Treatment Official Title: A Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of ABX-1431 in Patients With Central Pain Actual Study Start Date : August 1, 2017 Actual Primary Completion Date : July 23, 2018 Actual Study Completion Date : July 24, 2018 Resource links provided by the National Library of Medicine related topics: resources (...) with acute myelitis, and with chronic pain syndrome consistent with the lesion neuroanatomy may be enrolled. These LETM patients must also demonstrate evidence of acute, inflammatory myelopathy in the past (e.g. clinically acute symptomatic myelitis plus inflammatory CSF analysis (e.g. elevated WBC and IgG index) or imaging consistent with inflammatory myelopathy). LETM must be diagnosed at least 3 months prior to the screening visit. Patient with MS defined by McDonald criteria [1] or Poser criteria [2

2017 Clinical Trials

45. PEMF as Adjunctive Treatment Following Surgical Repair of Full Thickness Rotator Cuff Tears

Official Title: Prospective, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of Pulsed Electromagnetic Field (PEMF) Therapy as an Adjunctive Treatment to Surgical Repair of Full Thickness Rotator Cuff Tears Actual Study Start Date : January 15, 2018 Estimated Primary Completion Date : December 31, 2021 Estimated Study Completion Date : December 1, 2022 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm (...) imperfecta (OI) or Ehlers-Danlos syndrome (EDS). Subject has a known inflammatory or autoimmune connective tissue disease such as, but not limited to, gout affecting the shoulder, scleroderma, SLE, rheumatoid disease, or calcific tendonitis of the shoulder. Subject has a metabolic bone disease such as Paget's disease or osteomalacia. Subject has a deltoid defect, deltoid palsy or any other pseudoparalysis. Subject has HIV, hepatitis, or has had an active malignancy in the past 5 years. Subject has had

2017 Clinical Trials

46. The Confounding Burden of Psychological Impairments in Cervical Spine Surgery

classification: C2-C7 SVA > 8cm, Horizontal Gaze < -10 or > 25, T1S-CL > 20, myelopathy (JOA score <10) or severe adult spinal deformity based on SRS-Schwab classification (PI-LL > 20, PT >30, SVA > 90 mm) Undergoing simultaneous treatment for thoracolumbar spine related diagnoses at the time of enrollment History of any spinal surgery within the last 6 months Patients with neck pain attributable to trauma, idiopathic deformity, neoplasm, osteoporosis, or other medical condition. Unlikely to comply (...) : Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: The Confounding Burden of Psychological Impairments in Cervical Spine Surgery Actual Study Start Date : June 5, 2017 Estimated Primary Completion Date : April 3, 2019 Estimated Study Completion Date : April 3, 2019 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Active Comparator: Comparison Group Patients with a zero risk score

2017 Clinical Trials

47. Panzyga in CIDP Administered at Different Infusion Rates

the 12 months prior to baseline visit Respiratory impairment requiring mechanical ventilation Myelopathy or evidence of central nervous system demyelination or significant persisting neurological deficits from stroke, or central nervous system (CNS) trauma Clinical evidence of peripheral neuropathy from another cause such as connective tissue disease or systemic lupus erythematosus (SLE) HIV infection, hepatitis, Lyme disease cancer (with the exception of basal cell skin cancer) IgM paraproteinemia (...) ). Patients already receiving IVIG must be on 3- or 4-weekly IVIG treatment schedule with a calculated monthly dosage between 0.8 g/kg and 2.0 g/kg BW ≥ 18 years of age Voluntarily given, fully informed written consent obtained from patient before any study-related procedures are conducted For enrolment into the Second Phase: At each of the last three infusions in the First Phase, administration of panzyga® had to be at the maximum infusion rate of 0.08 mL/kg/min and good tolerated- assessment

2017 Clinical Trials

48. An Update of Comprehensive Evidence-Based Guidelines for Interventional Techniques in Chronic Spinal Pain - Part 2 - Guidance and Recommendations

TECHNIQUES V. MANAGEMENT OF LOW BACK PAIN 1.0 Disc-Related Pathology, Spinal Stenosis, And Radiculitis 1.1 Diagnosis Of Disc-Related Lumbar Pathology 1.1.1 Diagnostic Interventional Techniques 1.2 Therapeutic Interventions Of Lumbar Discogenic Pathology 1.2.1 Epidural Injections 1.2.2 Lumbar Epidural Adhesiolysis 1.2.3 Thermal Annular Procedures 1.2.4 Percutaneous Disc Decompression 2.0 Lumbar Facet Joint Pain 2.1 Diagnosis of Lumbar Facet Joint Pain 2.1.1 Diagnostic Lumbar Facet Joint Blocks 2.2 (...) Therapeutic Lumbar Facet Joint Interventions 2.2.1 Radiofrequency Neurotomy 2.2.2 Therapeutic Facet Joint Nerve Blocks 2.2.3 Intraarticular Injections 3.1.1 Diagnostic Sacroiliac Joint Blocks 3.2 Therapeutic Sacroiliac Joint Interventions 3.2.1 Intraarticular Injections 3.2.2 Periarticular Injections 3.2.3 Conventional Radiofreqency Neurotomy 3.2.4 Cooled Radiofrequency Neurotomy 3.2.5 Pulsed Radiofrequency Neurotomy VI. MANAGEMENT OF NECK PAIN 1.0 Disc-Related Pathology, Spondylosis, Spinal Stenosis

2013 American Society of Interventional Pain Physicians

49. Family Practice Notebook Updates 2016

and Genvoya are first line, one pill daily regimens for therapy naive, non-pregnant HIV patients based therapy with Atripla is no longer first-line therapy as of 2015 (uro, ) Treat suspected STD-related with IM 250 mg and oral 100 bid for 10 days Age over 35 and no concern for STD, treat with or for 10 days Insertive anal intercourse history should prompt 250 IM, then or for 10 days is inadequate for ( resistance) (lung, tb) (e.g. Quantiferon Gold) is a more accurate, reproducible test regardless of than (...) (or ingested) (e.g. lime or lemon) Use , eliminate and if inflamed, (neuro, cv, bleed) In suspected SAH, when is negative, LP is a true positive in 0.4%, and false positive in 4.2% (id, prevent) Highest infection risk is for an HBab negative exposed patient (30% risk if source is positive) For a positive source, HCV transmission is 1.8% and is 0.3% is available for HIV and HBV exposures (pharm, analgesia, ) is reponsible for 30% of prescription related deaths, but accounts for only 2% of the prescriptions

2018 FP Notebook

50. Abnormal Gait and Balance Causes in the Elderly

Administration 4 Abnormal Gait and Balance Causes in the Elderly Abnormal Gait and Balance Causes in the Elderly Aka: Abnormal Gait and Balance Causes in the Elderly II. Causes: Psychiatric Disorders Disorders III. Causes: Cardiovascular Disorders Arrhythmia IV. Causes: Infectious Disorders Induced (HIV-related ) V. Causes: Metabolic Disorders and VI. Causes: Musculoskeletal Disorders VII. Causes: Neurologic Disorders Cerebellar Degeneration Myelopathy Normal-pressure Vestibular disorders VIII. Causes (...) : Miscellaneous Hearing Medications IX. References Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Abnormal Gait and Balance Causes in the Elderly." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Related Topics in Examination About FPnotebook.com is a rapid access, point-of-care medical reference for primary care and emergency clinicians. Started in 1995

2018 FP Notebook

51. Safety and Preliminary Efficacy of FAB117-HC in Patients With Acute Traumatic Spinal Cord Injury

or significant impairment in the level of consciousness, including unconsciousness due to sedative-analgesic medications, that interferes with the performance or interpretation of assessments specific in the protocol. Preexisting or current significant diseases such as hepatitis C, HIV, epilepsy, neoplastic disease or other diseases that could cause neurological deficits including syphilis, myelopathy, and polyneuropathy. Background or acute episode of Guillain-Barre syndrome. History of meningitis (...) and Preliminary Efficacy of the Administration of FAB117-HC, a Drug Whose Active Ingredient is HC016, Allogeneic Adipose Derived Adult Mesenchymal Stem Cells Expanded and Pulsed With H2O2, in Acute Traumatic SCI Patients. Study Start Date : December 2016 Estimated Primary Completion Date : April 2019 Estimated Study Completion Date : January 2020 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: FAB117-HC (Ph 1

2016 Clinical Trials

52. Family Practice Notebook Updates 2016

and Genvoya are first line, one pill daily regimens for therapy naive, non-pregnant HIV patients based therapy with Atripla is no longer first-line therapy as of 2015 (uro, ) Treat suspected STD-related with IM 250 mg and oral 100 bid for 10 days Age over 35 and no concern for STD, treat with or for 10 days Insertive anal intercourse history should prompt 250 IM, then or for 10 days is inadequate for ( resistance) (lung, tb) (e.g. Quantiferon Gold) is a more accurate, reproducible test regardless of than (...) (or ingested) (e.g. lime or lemon) Use , eliminate and if inflamed, (neuro, cv, bleed) In suspected SAH, when is negative, LP is a true positive in 0.4%, and false positive in 4.2% (id, prevent) Highest infection risk is for an HBab negative exposed patient (30% risk if source is positive) For a positive source, HCV transmission is 1.8% and is 0.3% is available for HIV and HBV exposures (pharm, analgesia, ) is reponsible for 30% of prescription related deaths, but accounts for only 2% of the prescriptions

2017 FP Notebook

53. Abnormal Gait and Balance Causes in the Elderly

Administration 4 Abnormal Gait and Balance Causes in the Elderly Abnormal Gait and Balance Causes in the Elderly Aka: Abnormal Gait and Balance Causes in the Elderly II. Causes: Psychiatric Disorders Disorders III. Causes: Cardiovascular Disorders Arrhythmia IV. Causes: Infectious Disorders Induced (HIV-related ) V. Causes: Metabolic Disorders and VI. Causes: Musculoskeletal Disorders VII. Causes: Neurologic Disorders Cerebellar Degeneration Myelopathy Normal-pressure Vestibular disorders VIII. Causes (...) : Miscellaneous Hearing Medications IX. References Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Abnormal Gait and Balance Causes in the Elderly." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Related Topics in Examination About FPnotebook.com is a rapid access, point-of-care medical reference for primary care and emergency clinicians. Started in 1995

2017 FP Notebook

54. Sciatica (lumbar radiculopathy)

with acute low back pain have a herniated intervertebral disc [ ]. The incidence of sciatica is related to age, peaking in the 5th decade before declining. Sciatica is rarely seen in people younger than 20 years old [ ]. Causes What are the causes? Sciatica is caused by compression of one or more nerve roots in the lumbosacral spine. The compression can be caused by: A herniated intervertebral disc ('slipped disc') — about 90% of cases. This most commonly occurs at the L4/L5 and L5/S1 levels (...) . Anxiety, depression, and psychosocial impact on family. Time off work, reduced productivity, and loss of employment — non-specific low back pain is cited in some studies as being responsible for 11–13.5% of all time off work [ ]. The estimated working days lost in the UK in 2015–16 due to work-related back disorders was 3.4 million. On average each person took 15.9 days off work as a result of back pain [ ]. Risk factors What are the risk factors? There are differing opinions in the published

2015 NICE Clinical Knowledge Summaries

55. Multiple sclerosis

various neurological signs. There is often a history of tick bites, arthralgia, and rashes. For more information, see the CKS topic on . Tertiary syphilis — classically, dorsal column abnormalities with dementia. For more information, see the CKS topic on . HIV — can cause encephalopathy and myelopathy. For more information, see the CKS topic on . Tropical spastic paraparesis — caused by infection with human T-lymphotropic virus and is mainly seen in the Caribbean area. It causes a slowly progressive (...) , and female gender. Presenting symptoms and signs vary greatly, but the four most common presentations are optic neuritis, transverse myelitis, cerebellar related symptoms, and brainstem syndromes. The natural history of RRMS is unpredictable. The severity and frequency of relapses vary greatly, as can the time it takes to progress to SPMS and to significant permanent disability. It is difficult to give a person an estimate of their disease course and likely outcome. Treatment with disease modifying

2015 NICE Clinical Knowledge Summaries

56. Thoracic Aortic Disease: Guidelines For the Diagnosis and Management of Patients With

the evidence related to drugs, devices, and procedures for the detection, management, or prevention of disease. Properly applied, rigorous, expert analysis of the available data documenting absolute and relative bene?ts and risks of these therapies and procedures can improve outcomes and reduce costs of care by focusing resources on the most effective strategies. One important use of such data is the production of clinical practice guidelines that, in turn, can provide a foundation for a variety of other (...) readers’ comprehension of the guidelines and will allow queries at the individual recommendation level. e33 JACC Vol. 55, No. 14, 2010 Hiratzka et al. April 6, 2010:e27–129 2010 Guidelines on Thoracic Aortic Diseasecomes for performance improvement. The UHC provided the writing committee with a summary of recent information based on ICD-9 codes for thoracic aortic disease–related hospitalizations from the Clinical DataBase/Resource Man- ager (Tables 2A and 2B). This data table demonstrates a high

2010 American College of Cardiology

57. Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy

minimum clinically important difference (MCID) cut-off of 8 kilopascal (kPa) Inflammatory Rasch-built overall disability scale (I-RODS Score) [ Time Frame: at Week 24 ] Proportion of responders in the 0.5 g/kg and 2.0 g/kg NewGam arms at Week 24 relative to baseline at Week 0 compared to the 1.0 g/kg arm, based on the Inflammatory Rasch-built overall disability scale (I-RODS Score) using the MCID concept related to the varying standard errors (MCID-SE) as recently demonstrated Worsening (...) before any study-related procedures are conducted Exclusion Criteria: Unifocal forms of Chronic inflammatory demyelinating polyneuropathy (CIDP) Pure sensory Chronic inflammatory demyelinating polyneuropathy (CIDP) Multifocal motor neuropathy (MMN) with conduction block [van den Bergh et al., 2010] Patients who previously failed immunoglobulin treatment Treatment with immunomodulatory/suppressive agents (cyclosporin, methotrexate, mitoxantrone, mycophenolate mofetil or azathioprine) during the six

2015 Clinical Trials

58. Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma

Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma Actual Study Start Date : June 3, 2016 Actual Primary Completion Date : November 30, 2017 Resource links provided by the National Library of Medicine related topics: available for: resources: Arms and Interventions Go to Arm Intervention/treatment Experimental: Treatment (nivolumab) Patients receive nivolumab IV over (...) including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements Any condition requiring > 10 mg/d prednisone equivalents Current or prior HTLV-1 associated inflammatory diseases, including but not limited to myelopathy, uveitis, arthropathy, pneumonitis, or a Sjogren's disease-like disorder Prior treatment with anti-PD-1, anti

2015 Clinical Trials

59. Effect of Raltegravir in Patients With Acute Tropical Spastic Paraparesis

Purpose: Treatment Official Title: Effect of Raltegravir in Patients With Myelopathy/Tropical Spastic Paraparesis Associated With Infection by Human T-Lymphotropic Virus 1 (HTLV-1). Pilot Study Actual Study Start Date : July 1, 2017 Estimated Primary Completion Date : June 2018 Estimated Study Completion Date : June 2019 Resource links provided by the National Library of Medicine related topics: available for: resources: Arms and Interventions Go to Arm Intervention/treatment Experimental: HTLV-1 plus (...) Status : Recruiting First Posted : January 14, 2016 Last Update Posted : November 22, 2017 See Sponsor: Universidad Peruana Cayetano Heredia Collaborator: Merck Sharp & Dohme Corp. Information provided by (Responsible Party): Universidad Peruana Cayetano Heredia Study Details Study Description Go to Brief Summary: This is a pilot study of intervention in a group of patients with tropical spastic paraparesis/ myelopathy to evaluate virologic and clinical response of raltegravir plus zidovudine

2015 Clinical Trials

60. Prospective Comparative Study to Compare Safety and Effectiveness of Two Vertebral Compression Fracture Reduction Techniques

, Comparative Clinical Study to Compare the Safety and Effectiveness of Two Vertebral Compression Fracture (VCF) Reduction Techniques: the SpineJack® and the KyphX Xpander® Inflatable Bone Tamp Study Start Date : April 2015 Actual Primary Completion Date : February 20, 2018 Actual Study Completion Date : February 20, 2018 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: SpineJack® system VCF treatment system (...) and effectiveness): Reduction in VCF fracture-related pain at 12 months from baseline as measured by a 100 mm VAS scale (reduction of pain at 12 months by > 20 mm) AND, Maintenance or improvement in function at 12 months from baseline as measured by the 100 point Oswestry Disability Index (ODI) AND, Absence of device-related serious adverse events, defined as device-related adverse events (device migration, recollapse, protrusion) or symptomatic cement extravasation requiring surgical re-intervention

2015 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>